Sarju Patel
Uveitis and Ocular Inflammatory Disease · Sacramento, CANPI 1730384876
Payments from drug & device makers
Across 319 payments — averaging $432.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$50K
- Alimera Sciences, Inc.$28K
- ANI Pharmaceuticals, Inc.$13K
- Regeneron$10K
- Biogen$10K
- Genentech USA, Inc.$8K
- plus $19K from 19 others
What the payments were for
- Consulting fees$28,65830%
- Speaking & faculty fees$47,41449%
- Travel & lodging$7,4098%
- Food & beverage$13,10014%
- Gifts$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $49,870 |
| Alimera Sciences, Inc. | 24 | $27,547 |
| ANI Pharmaceuticals, Inc. | 13 | $13,175 |
| Regeneron | 18 | $10,167 |
| Biogen | 29 | $10,013 |
| Genentech USA, Inc. | 34 | $8,222 |
| Eyepoint US, Inc. | 11 | $6,902 |
| Apellis Pharmaceuticals, Inc. | 29 | $5,045 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $1,884 |
| Astellas Pharma US Inc | 15 | $826 |
| Regeneron Healthcare Solutions, Inc. | 16 | $793 |
| Novartis | 14 | $700 |
| Alcon | 4 | $561 |
| Mallinckrodt Hospital Products Inc. | 22 | $493 |
| Bausch & Lomb Americas Inc. | 10 | $452 |
| Biotissue Holdings Inc. | 4 | $346 |
| Coherus Oncology, Inc. | 3 | $282 |
| Genentech, Inc. | 7 | $200 |
| Amgen(2 entities) | 3 | $167 |
| Harrow Eye, LLC | 2 | $142 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Neurotech Pharmaceuticals, Inc. | 3 | $53 |
| Carl Zeiss Meditec AG | 2 | $39 |
| GSK | 1 | $35 |
| Thea Pharma Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few uveitis and ocular inflammatory disease providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 13 | $82,587 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 65 | $9,848 |
| Prednisolone Acetate | 186 | $8,219 |
| Difluprednate | 51 | $5,397 |
| Acetazolamide | 168 | $5,208 |
| LumiganBimatoprost | 11 | $4,684 |
| Latanoprost | 212 | $2,981 |
| Mycophenolate Mofetil | 16 | $2,920 |
| Fluorometholone | 29 | $2,667 |
| ValacyclovirValacyclovir Hcl | 28 | $2,196 |
| Timolol Maleate | 123 | $1,850 |
| Ketorolac Tromethamine | 74 | $1,768 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 85 | $1,406 |
| Ofloxacin | 99 | $1,004 |
| Brimonidine Tartrate | 66 | $730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Lumigan | $49,870 | $87,27124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few uveitis and ocular inflammatory disease providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other uveitis and ocular inflammatory disease in Sacramento
- Quan NguyenStanford$2.8M
- Edmund TsuiLos Angeles$427K
- Olivia LeeIrvine$16K
- Judy ChenPasadena$1K
- Jennifer LeeSantee$555
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.